MedTrace Logo

AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer

NCT05617755 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2025-07-30

No results posted yet for this study

Summary

This is a multi-center, open-label phase 1 dose escalation trial that uses a modified 3+3 design to identify a recommended phase 2 dose (RP2D) of AB-1015 cell product. Backfill cohorts will enroll additional subjects at doses deemed to be safe for a total enrollment of up to 12 subjects per each backfill cohort on the protocol.

Conditions

  • Carcinoma, Ovarian Epithelial
  • Ovarian Neoplasms
  • Fallopian Tube Neoplasms
  • Peritoneal Neoplasms
  • Neoplasms, Glandular and Epithelial
  • Ovarian Diseases
  • Genital Neoplasm, Female
  • Abdominal Neoplasm
  • Recurrence

Interventions

BIOLOGICAL

AB-1015

autologous T cell therapy

Sponsors & Collaborators

  • Arsenal Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Arsenal Biosciences · Arsenal Biosciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-29
Primary Completion
2024-09-30
Completion
2027-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05617755 on ClinicalTrials.gov